Zobrazeno 1 - 10
of 211
pro vyhledávání: '"Steven J, O'Day"'
Autor:
Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer
Externí odkaz:
https://doaj.org/article/07dff5f507bc4d64bce5f819f24c264d
Autor:
F. Stephen Hodi, Jonathan A. Fletcher, Christopher L. Corless, Boris C. Bastian, Michael C. Heinrich, Cristina R. Antonescu, Anita Giobbie-Hurder, Nikhil Ramaiya, Jerrold B. Teitcher, Ryan J. Sullivan, Paul B. Chapman, Jedd D. Wolchok, Omid Hamid, Steven J. O'Day, Jose Lutzky, Rene Gonzalez, Thomas F. Gajewski, Jeffrey S. Weber, Donald P. Lawrence, Richard D. Carvajal
Supplemental Table 1. Adverse events observed and adjudicated as possibly, probably or definitely related to therapy (n = 19).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f012a7ac69436fee0916e329753f691
https://doi.org/10.1158/1078-0432.22456574
https://doi.org/10.1158/1078-0432.22456574
Autor:
Steven J. O'Day, Jonathan Siegel, David Berman, Anthony Maraveyas, Hazem Assi, Ruggero Ridolfi, Ilan Ron, Asim Amin, David Minor, Omid Hamid, John A. Thompson, Jeffrey Weber
Supplementary Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb966dc51bbba4300f3da2c49abf3e2
https://doi.org/10.1158/1078-0432.22440760.v1
https://doi.org/10.1158/1078-0432.22440760.v1
Autor:
Steven J. O'Day, Jonathan Siegel, David Berman, Anthony Maraveyas, Hazem Assi, Ruggero Ridolfi, Ilan Ron, Asim Amin, David Minor, Omid Hamid, John A. Thompson, Jeffrey Weber
Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f84bdb2347ee6e3095b875e3aca0676
https://doi.org/10.1158/1078-0432.c.6518050.v1
https://doi.org/10.1158/1078-0432.c.6518050.v1
Autor:
Richard F. Kefford, Daniele Ouellet, Bo Ma, Peter Lebowitz, C. Martin Curtis, Samuel C. Blackman, Steven J. O'Day, Melvin T. Chin, Anna Pavlick, Michael Millward, Jeffrey R. Infante, Omid Hamid, Michael P. Brown, H.-Tobias Arkenau, Kevin B. Kim, Razelle Kurzrock, Georgina V. Long, Gerald S. Falchook
Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose selection in the first-in-human study of dabrafenib, including phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced035f5a9c3adb4d6d3ba6e5392e18d
https://doi.org/10.1158/1078-0432.c.6522927.v1
https://doi.org/10.1158/1078-0432.c.6522927.v1
Autor:
Richard F. Kefford, Daniele Ouellet, Bo Ma, Peter Lebowitz, C. Martin Curtis, Samuel C. Blackman, Steven J. O'Day, Melvin T. Chin, Anna Pavlick, Michael Millward, Jeffrey R. Infante, Omid Hamid, Michael P. Brown, H.-Tobias Arkenau, Kevin B. Kim, Razelle Kurzrock, Georgina V. Long, Gerald S. Falchook
Table S1. Treatment-related adverse events of {greater than or equal to} grade 2 reported in at least 5% of patients by dose (3); Table S2. Summary of plasma dabrafenib pharmacokinetic parameters after single-dose administration of dabrafenib gelatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6954178cfdd02cc0e6fa2fbb6ada516a
https://doi.org/10.1158/1078-0432.22455123
https://doi.org/10.1158/1078-0432.22455123
Autor:
F. Stephen Hodi, Jonathan A. Fletcher, Christopher L. Corless, Boris C. Bastian, Michael C. Heinrich, Cristina R. Antonescu, Anita Giobbie-Hurder, Nikhil Ramaiya, Jerrold B. Teitcher, Ryan J. Sullivan, Paul B. Chapman, Jedd D. Wolchok, Omid Hamid, Steven J. O'Day, Jose Lutzky, Rene Gonzalez, Thomas F. Gajewski, Jeffrey S. Weber, Donald P. Lawrence, Richard D. Carvajal
Purpose: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7341e7297429cd0bab5ed0c6088146a8
https://doi.org/10.1158/1078-0432.c.6523355.v1
https://doi.org/10.1158/1078-0432.c.6523355.v1
Autor:
Félix Couture, Victoria Atkinson, Steven L. McCune, Alexander M. Menzies, Geoffrey T. Gibney, Andrew G. Hill, Georgina V. Long, Cuizhen Niu, Michael P. Brown, Blanca Homet Moreno, Stéphane Dalle, Steven J. O'Day, Caroline Robert, Matteo S. Carlino, Marcus O. Butler, Nageatte Ibrahim, Adi Diab, Jonathan Cebon
Publikováno v:
Clin Cancer Res
Purpose: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose pembr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f67743e03a6f91b67256825f8dfc5bc
https://doi.org/10.1158/1078-0432.ccr-21-0793
https://doi.org/10.1158/1078-0432.ccr-21-0793
Autor:
Ann W. Silk, Steven J. O’Day, Howard L. Kaufman, Jennifer Bryan, Jacqueline T. Norrell, Casey Imbergamo, Daniella Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Seymour Fein, Cai Wu, Leslie Guerreiro, Daniel Medina, Praveen K. Bommareddy, Andrew Zloza, Bernard A. Fox, Carmen Ballesteros-Merino, Yixin Ren, Darren Shafren, Mark Grose, Joshua A. Vieth, Janice M. Mehnert
Publikováno v:
Cancer immunology, immunotherapy : CII.
Background CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma. Methods Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f9d368838c23309ed35e63e7b2a991a
https://pubmed.ncbi.nlm.nih.gov/36445410
https://pubmed.ncbi.nlm.nih.gov/36445410
Autor:
Bin Zhang, F. Stephen Hodi, Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Stephen Francis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant admi
Externí odkaz:
https://doaj.org/article/0f77214448854233aa98f583d805a4de